Cohypermethylation of XXXX and @entity21900 promoters as a prognostic factor of recurrence in surgically resected stage I @entity1149 .

@entity1 @entity986 @entity1149 @entity2 @entity4191 @entity21900
Despite advances in the detection and treatment of @entity2 , the prognosis for @entity1 with @entity2 is poor, partly as a result of recurrences. We retrospectively analyzed the relationship between recurrence and survival in @entity1 with @entity1149 ( @entity1149 ), and the promoter methylation of @entity986 , @entity4191 , @entity21900 , H-cadherin, and RARbeta2 genes to identify a prognostic molecular marker associated with the recurrence of @entity1149 . Methylation status from 335 paraffin blocks was determined by methylation-specific PCR. Of the 335 @entity1149 samples, promoter methylation was detected in 35% for @entity986 , 39% for RARbeta2, 42% for H-cadherin, 7% for @entity4191 , and 21% for @entity21900 . Recurrence was observed in 39% (132 of 335) of the @entity1 . Recurrence was significantly associated with histology (P = 0.001) and pathologic stage (P = 0.009). Hypermethylation of any single gene was not associated with recurrence in @entity1 . However, cohypermethylation of @entity986 and @entity21900 genes in stage I NSCLCs was associated with an increased risk of recurrence [odds ratio, 6.43; 95% confidence interval (CI), 1.04-20.19; P = 0.02] and poor recurrence-free survival after surgery (hazard ratio, 2.03; 95% CI, 1.09-6.23; P = 0.02). In addition, their survival after recurrence was also 4.62 times poorer (95% CI, 1.27-16.48; P = 0.005) than for those without cohypermethylation of both genes. In conclusion, the present study suggests that cohypermethylation of @entity986 and @entity21900 genes in @entity1 with stage I @entity1149 may be a valuable biomarker for predicting the recurrence-associated prognosis of the disease.
